- Home
- PSTL vs PHAT Comparison
PSTL vs PHAT Comparison
Compare PSTL & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSTL
- PHAT
- Stock Information
- Founded
- PSTL 2018
- PHAT 2018
- Country
- PSTL United States
- PHAT United States
- Employees
- PSTL N/A
- PHAT N/A
- Industry
- PSTL Real Estate Investment Trusts
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- PSTL Real Estate
- PHAT Health Care
- Exchange
- PSTL Nasdaq
- PHAT Nasdaq
- Market Cap
- PSTL 335.6M
- PHAT 339.8M
- IPO Year
- PSTL 2019
- PHAT 2019
- Fundamental
- Price
- PSTL $13.43
- PHAT $4.03
- Analyst Decision
- PSTL Strong Buy
- PHAT Strong Buy
- Analyst Count
- PSTL 1
- PHAT 5
- Target Price
- PSTL $15.50
- PHAT $22.50
- AVG Volume (30 Days)
- PSTL 165.9K
- PHAT 1.2M
- Earning Date
- PSTL 05-06-2025
- PHAT 05-08-2025
- Dividend Yield
- PSTL 7.23%
- PHAT N/A
- EPS Growth
- PSTL 83.16
- PHAT N/A
- EPS
- PSTL 0.21
- PHAT N/A
- Revenue
- PSTL $76,372,000.00
- PHAT $55,252,000.00
- Revenue This Year
- PSTL $13.87
- PHAT $202.23
- Revenue Next Year
- PSTL $10.76
- PHAT $113.81
- P/E Ratio
- PSTL $63.07
- PHAT N/A
- Revenue Growth
- PSTL 19.87
- PHAT 8001.47
- 52 Week Low
- PSTL $12.26
- PHAT $3.81
- 52 Week High
- PSTL $15.15
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- PSTL 47.66
- PHAT 38.04
- Support Level
- PSTL $12.52
- PHAT $3.81
- Resistance Level
- PSTL $14.35
- PHAT $5.09
- Average True Range (ATR)
- PSTL 0.41
- PHAT 0.68
- MACD
- PSTL -0.05
- PHAT -0.10
- Stochastic Oscillator
- PSTL 53.30
- PHAT 7.72
About PSTL Postal Realty Trust Inc.
Postal Realty Trust Inc is an internally managed real estate corporation that owns and manages properties leased to the United States Postal Service, or the USPS. Its objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of the revenue is generated from the rental income received.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.